Dopexamine in congestive heart failure: how do the pharmacological activities translate into the clinical situation?

1989 ◽  
Vol 84 (1) ◽  
pp. 177-186 ◽  
Author(s):  
T. Meinertz ◽  
H. Drexler ◽  
Hj. Just
Keyword(s):  
Heart Failure ◽  
Congestive Heart Failure ◽  
Clinical Situation ◽  
Pharmacological Activities

In Reply: Common Clinical Cardiological Problems: The Absence of Arbitrary Answers

PEDIATRICS ◽  
1973 ◽  
Vol 52 (4) ◽  
pp. 620-621
Author(s):  
Jacqueline A. Noonan
Keyword(s):  
Heart Failure ◽  
Congestive Heart Failure ◽  
Congenital Heart Disease ◽  
Heart Disease ◽  
Medical Students ◽  
Congenital Heart ◽  
Good Deal ◽  
Clinical Situation ◽  
Pediatric Cardiologist ◽  
Basic Understanding

The comments above by Drs. Silver and Joos pertain to some important and quite complicated clinical situations. They pose questions which do not lend themselves to simple arbitrary recommendations by the Academy. All involve a good deal of basic understanding of the pathophysiology of congestive heart failure and congenital heart disease in general. I doubt a simple arbitrary recommendation of any of the listed problems could be given which would cover every clinical situation. Active participation by trained pediatric cardiologist in both the training of medical students and house staff is, of course, a good and usual way for "future" pediatricians to learn how to manage "common pediatric cardiologic problems."

Care of the Elderly Mechanically Ventilated Patient: Preserving the Fragile Environment

1992 ◽  
Vol 3 (1) ◽  
pp. 129-136
Author(s):  
Johanna K. Stiesmeyer
Keyword(s):  
Heart Failure ◽  
Blood Pressure ◽  
Elderly Patient ◽  
Congestive Heart Failure ◽  
Minute Ventilation ◽  
The Elderly ◽  
Clinical Situation ◽  
Course Of Illness ◽  
Mechanically Ventilated ◽  
Fragile Environment

Caring for the elderly mechanically ventilated patient is a challenging and increasingly frequent clinical situation confronting critical nurses. The key complications and states to which the elderly patient is particularly susceptible are nosocomial pneumonia; congestive heart failure; malnutrition; reactions to medications, especially antibiotics, morphine sulfate, and Valium; changes in mental status, and pneumothorax. These can significantly contribute to multisystem deterioration. It is unclear which mode of ventilation is best for sustaining the patient during the course of illness or the weaning process. It is critical to recognize the assessment indicators of failed weaning. Paramount in this assessment are rapid shallow breaths, change in blood pressure of 20 mmHg, change in respiratory rate of more than 10 breaths per minute, tidal volume of less than 250 to 300 mL, a minute ventilation with an increase of 5 L/minute, and an oxygen saturation of less than 90% per pulse oximeter. Research in these areas is needed

TORASEMIDE FOR THE TREATMENT OF HEART FAILURE

2021 ◽  
pp. 27-30
Author(s):  
Harshawardhan Dhanraj Ramteke ◽  
Roshan Rajesh Menon
Keyword(s):  
Heart Failure ◽  
Congestive Heart Failure ◽  
Loop Diuretic ◽  
Symptomatic Relief ◽  
Left Ventricular ◽  
Functional Class ◽  
Line Treatment ◽  
Pharmacological Activities ◽  
Nyha Functional Class

Diuretics play a major role in the rst line treatment for the Congestive Heart Failure (CHF). These diuretics are currently and majorly used for symptomatic relief. Torasemide, a loop diuretic, is a newly developed loop diuretic, which has a longer half-life, longer duration for action, and higher bioavailability as compared to the other loop diuretics like furosemide. Torasemide, also works more effectively for the anti-aldosterone effect and vasorelaxation effect. Several studies have also suggested that torasemide has superior pharmacokinetics and pharmacological activities than that of furosemide. Results of several studies state that torasemide helps in improving the left ventricular function, reduces the mortality, as well as the frequency and duration of heart failure. Torasemide also improves the quality of life, tolerance and NYHA functional class in patients suffering from CHF. Based on these results, torasemide appears to be a promising loop diuretic for the rst line treatment and for better management of the patients with CHF. In this review, we provide a panorama of existing knowledge on the properties of torasemide, aimed at using it as a rst line of treatment for the patients in Congestive Heart Failure (CHF).

Sign in / Sign up

Export Citation Format

Share Document